Toggle Health Problems and D

Vitamin D cost-effectively treats Multiple Sclerosis – July 2021

Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project

Mult Scler Relat Disord. 2021 Jun 30;54:103107. doi: 10.1016/j.msard.2021.103107 PDf is behind a paywall
Michela Tinelli 1, Maura Pugliatti 2, Andreea Antonovici 3, Bettina Hausmann 3, Kerstin Hellwig 4, Vinciane Quoidbach 5, Per Soelberg Sørensen 6

 Previous conference presentation by similar authors, similar title


Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019

UV and Sunshine reduces MS risk

Other things also help

High Dose Vitamin D and cofactors

Number of MS studies which are also in other categories

  • 21 studies in Genetics - genes can restrict Vitamin D getting to the blood and to the cells
  • 11 studies in Vitamin D Receptor - gene which restricts D from getting to the cells
  • 7 studies in Vitamin D Binding Protein - gene which restricts D from getting to the cells
  • 21 studies in Ultraviolet light - may be even better than Vitamin D in preventing and treating MS
  • 9 studies in Omega-3 - which helps Vitamin D prevent and treat MS

Background and purpose: The recent report on Value-of-Treatment (VoT) project highlights the need for early diagnosis-intervention, integrated, seamless care underpinning timely care pathways and access to best treatments. The VoT-multiple-sclerosis (MS) economic case study analysis aimed to estimate the effectiveness/cost-effectiveness of both early treatment and reducing MS risk factors (e.g. smoking and vitamin D insufficiency).

Methods: A series of decision analytical modellings were developed and applied to estimate the cost-effectiveness of: (1) reducing the conversion from clinically-isolated-syndrome (CIS) to clinically-definite-MS (CDMS); (2) smoking cessation and increase of 25 hydroxyvitamin D (25(OH)D) serum level. Both (1) and (2) considered socioeconomic impact on averted MS disability progression. Costs were reported for societal and healthcare provider perspectives (pending on data across nations; Euros). Effectiveness was expressed as Quality-Adjusted-Life-Years (QALYs) gains. Long term (25, 30, 40,50-years) and short (one-year) timelines were considered for (1) and (2), respectively.

Results: Early treatment was cost-effective for the health care provider and both cost-effective/cost-saving for the society across time-horizons and nations. Smoking cessation and an increase of 25(OH)D in MS patients were both cost-effective/cost-saving across nations.

Conclusions: To the best of our knowledge, our work provides the first economic evidence to base appropriate public health interventions to reduce the MS burden in Europe.

Title change made June 2022 caused the visitor count to reset.
There have actually been 1525 visitors to this page since it was originally made

Created by admin. Last Modification: Tuesday June 28, 2022 21:24:03 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
18002 Averting multiple sclerosis long-term societal .pdf admin 28 Jun, 2022 21:16 183.96 Kb 89